Asset profile
tesofensine
Small molecule
Evidence outlook · lead readout
NCT00481104 · Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT00481104: This was an unblinded, single-group study without a comparator, involving 140 participants who had completed TIPO-1. Its primary endpoint was safety, but results and any primary-endpoint comparison are not posted; its status as a documented long-term extension of TIPO-1 supports a moderate evidence grade.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.